236 related articles for article (PubMed ID: 36341402)
1. Impaired intratumoral natural killer cell function in head and neck carcinoma.
Mele D; Pessino G; Trisolini G; Luchena A; Benazzo M; Morbini P; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Front Immunol; 2022; 13():997806. PubMed ID: 36341402
[TBL] [Abstract][Full Text] [Related]
2. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
3. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
[TBL] [Abstract][Full Text] [Related]
5. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
8. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
9. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
12. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
13. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
20. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]